The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions

Jördis J Ott, Gretchen A Stevens, Steven T Wiersma, Jördis J Ott, Gretchen A Stevens, Steven T Wiersma

Abstract

Background: HBeAg presence in childbearing-age women is a major determinant of perinatal hepatitis B virus (HBV) transmission. The risk of developing chronic HBV infection and liver disease is highest at young age. Our aim was to assess perinatal HBV transmission risk by means of estimating age- and region-specific HBeAg prevalence.

Methods: Based on observed HBeAg seroprevalence data obtained from a systematic literature review, we modeled HBeAg prevalence using an empirical Bayesian hierarchical model. Age- and region-specific estimates were generated for 1990 and 2005.

Results: Globally, highest HBeAg prevalence of over 50 % was found in 0-9 years old girls. At reproductive age, HBeAg prevalence was 20-50 %. Prevalence was highest in young females in East Asia in 1990 (78 %), the infection was less common in Sub-Saharan and North Africa. Regional differences in prevalence were smaller in 2005. There was an overall decrease in HBeAg between 1990 and 2005, which was strongest among girls in Oceania (23.3 % decline), South and South-East Asia (14 % decline). However, in these regions, prevalence remained high at 67 % among young females in 2005. Smaller decreases were observed in women at reproductive age, at which 24-32 % of all HBsAg-positive women were HBeAg-positive in 2005, with lowest prevalence in Southern Sub-Saharan Africa and highest prevalence in Oceania and South-East Asia.

Conclusions: HBeAg estimates are crucial for understanding the epidemiology of HBV and for prioritizing implementation of WHO`s prevention recommendations for all infants to receive the first dose of hepatitis B vaccine within 24 hours of birth. Results will have importance as access to treatment for chronic HBV infection is expanded.

Figures

Figure 1
Figure 1
HBeAg among HBsAg-positive females, 1990.
Figure 2
Figure 2
HBeAg among HBsAg-positive females, 2005.
Figure 3
Figure 3
HBeAg prevalence among HBsAg-positive females by GBD region, 0–9 years, 1990 and 2005.
Figure 4
Figure 4
HBeAg prevalence among HBsAg-positive females by GBD region, 20–39 years, 1990 and 2005.

References

    1. World Health Organization. Hepatitis B vaccines. Weekly epidemiological record 2009. , ; 2009. pp. 20–405.
    1. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM, Janssen RS, Ward JW. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1–33.
    1. Ni YH. Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol. 2011;46:1–8.
    1. Beasley RP. Rocks along the road to the control of HBV and HCC. Ann Epidemiol. 2009;19:231–234. doi: 10.1016/j.annepidem.2009.01.017.
    1. Dwivedi M, Misra SP, Misra V, Pandey A, Pant S, Singh R, Verma M. Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission. Indian J Gastroenterol. 2011;30:66–71. doi: 10.1007/s12664-011-0083-y.
    1. Edmunds WJ, Medley GF, Nokes DJ, O`Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996;117:313–325. doi: 10.1017/S0950268800001497.
    1. Knorr B, Maul H, Schnitzler P. Prevalence of hepatitis B virus infection among women at reproductive age at a German university hospital. J Clin Virology. 2008;42:422–4. doi: 10.1016/j.jcv.2008.03.009.
    1. Shao ZJ, Zhang L, Xu JQ, Xu DZ, Men K, Zhang JX, Cui HC, Yan YP. Mother-to-infant transmission of hepatitis B virus: a Chinese experience. J Med Virol. 2011;83:791–5. doi: 10.1002/jmv.22043.
    1. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow up study. J Pediatr. 1998;133:374–7. doi: 10.1016/S0022-3476(98)70272-0.
    1. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, Maley MW, Ayres A, Locarnini SA, Levy MT. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190:489–92.
    1. Shikata T, Karasawa T, Abe K. et al.Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis. 1977;136:571–6. doi: 10.1093/infdis/136.4.571.
    1. Alter HJ, Seeff LB, Kaplan PM. et al.Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med. 1976;295:909–13. doi: 10.1056/NEJM197610212951701.
    1. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105:94–8.
    1. Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med. 2007;12:160–167. doi: 10.1016/j.siny.2007.01.013.
    1. McMahon BJ, Alward WL, Hall DB. et al.Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599–603. doi: 10.1093/infdis/151.4.599.
    1. Chang MH, Sung JL, Lee CY. et al.Factors affecting clearance of hepatitis Be antigen in hepatitis B surface antigen carrier children. J Pediatr. 1989;115:385–390. doi: 10.1016/S0022-3476(89)80836-4.
    1. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol. 2011;55:183–191. doi: 10.1016/j.jhep.2010.12.030.
    1. Grosheide PM, Wladimiroff JW, Heijtink RA, Mazel JA, Christiaens GCML, Nuijten ASM, Schaldm SW. the Dutch Study Group on Prevention of Neonatal hepatitis. Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. BMJ. 1995;311:99–1197. doi: 10.1136/bmj.311.6997.99.
    1. Op de Coul EL, Hahne S, van Weert YW, Oomen P, Smit C, van der Ploeg KP, Notermans DW, Boer K, Van der Sande MA. Antenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective. BMC Infect Dis. 2011;11:185. doi: 10.1186/1471-2334-11-185.
    1. Global Burden of Diseases, Injuries and Risk Factors Study 2005. Global Burden of Diseases, Injuries and Risk Factors Study operations manual (final draft, January 2009) 2009. Available from .
    1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HbsAg seroprevalence and endemicity. Accepted for publication in Vaccine, in press.
    1. DISMOD III. 2011. , data modeled in June 2011.
    1. Beckers K, Schaad UB, Heininger U. Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns. Eur J Pediatr. 2004;163:654–657.
    1. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995;22:1387–1392.
    1. Oshitani H, Kasolo FC, Mpabalwani M, Mizuta K, Luo NP, Suzuki H, Numazaki Y. Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia. Trans R Soc Trop Med Hyg. 1996;90:235–236. doi: 10.1016/S0035-9203(96)90227-8.
    1. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T. et al.Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology. 2003;37:19–26. doi: 10.1053/jhep.2003.50036.
    1. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122:1756–1762. doi: 10.1053/gast.2002.33588.
    1. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005;43:411–417. doi: 10.1016/j.jhep.2005.03.018.
    1. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH. et al.Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133:1452–1457. doi: 10.1053/j.gastro.2007.08.010.
    1. Olinger CM, Venard V, Njayou M, Oyefolu AO, Maïga I, Kemp AJ, Omilabu SA, le Faou A, Muller CP. Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and recombinations. J Gen Virol. 2006;87:1163–1173. doi: 10.1099/vir.0.81614-0.
    1. Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Acharya SK, Gish RG, Kramvis A, Kew MC, Yoshihara N, Shrestha SM, Khan M, Miyakawa Y, Mizokami M. A case–control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology. 2004;40:747–755. doi: 10.1002/hep.20365.
    1. Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, Oh JK, Park S, Kim YJ, Shin HR, Yoo KY, Park SK. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011;128:176–184. doi: 10.1002/ijc.25321.
    1. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–174. doi: 10.1056/NEJMoa013215.
    1. Wiersma ST, McMahon B, Pawlotsky JM, Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int. 2010. [Epub ahead of print]
    1. Guidozzi F, Schoub BD, Johnson S, Song E. Should pregnant urban south African women be screened for hepatitis B? S Afr Med J. 1993;83:103–5.
    1. Madzime S, Adem M, Mahomed K, Woelk GB, Mudzamiri S, Williams MA. Hepatitis B virus infection among pregnant women delivering at Harare Maternity Hospital, Harare Zimbabwe, 1996 to 1997. Cent Afr J Med. 1999;45:195–8.
    1. Sriprakash I, Anil TP. Routine prenatal screening of Indian women for HBsAg: benefits derived versus cost. Trop Doct. 1997;27:176–7.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever